Arcus Biosciences, Inc.

Arcus Biosciences reported a net loss of $91 million for the second quarter of 2026, a significant decline from break-even in the prior year period. Total revenues for the quarter decreased to $41 million from $160 million year-over-year. For the six months ended June 30, 2026, the company posted a net loss of $219 million, compared to $112 million in the same period of 2025. The collaboration term with Gilead Sciences for new programs ended in July 2026, following Gilead's decision not to make an option continuation payment, and Gilead had previously terminated rights to the etrumadenant program in Q2 2025.

Arcus Biosciences reported a net loss of $91 million for the second quarter of 2026, a significant decrease from break-even in the prior year, with revenues falling to $41 million from $160 million. The company announced the discontinuation of the Phase 3 PACIFIC-8 study for its anti-TIGIT program (domvanalimab) with AstraZeneca, leading to Gilead relinquishing its board seats. Despite these setbacks, Arcus is aggressively advancing its casdatifan program for clear cell renal cell carcinoma with new clinical collaborations and expects multiple data readouts in the second half of 2026, maintaining a cash runway until at least the second half of 2028.

Arcus Biosciences reported Q1 2026 revenues of $17 million, down from $28 million in Q1 2025, and a net loss of $128 million, compared to $112 million in the prior year. The company announced the discontinuation of the Phase 3 STAR-121 study for domvanalimab plus zimberelimab in NSCLC due to futility. Arcus is advancing casdatifan for ccRCC, with Phase 3 enrollment expected by year-end 2026, and is progressing its inflammation and immunology pipeline with AB102 entering the clinic in Q3 2026. The company maintains a cash runway until at least H2 2028.